

Company	Compound	Phase	Indication & Inclusion Criteria	Locations	Clinical Trial
Exon Skipping					
NS Pharma Nippon Shinyaku	NS-089/ NCNP-02	Phase II	Duchenne Muscular Dystrophy 4 years to 14 years Ambulatory Amenable to exon 44 skipping	USA (CO, FL, GA, IL, KS, OH, PA, TX, VA) AUS, CAN, JPN, NZL, KOR, TUR	NCT05996003
NS Pharma Nippon Shinyaku	NS-050/ NCNP-03	Phase I & II	Duchenne Muscular Dystrophy 4 years to 14 years Ambulatory Amenable to exon 50 skipping	USA (CA, CO, IL, KS, PA) CAN, JPN, KOR, TUR	NCT06053814 (Meteor50)
Entrada	ELEVATE-44-201	Phase I & II	Duchenne Muscular Dystrophy 4 years to 20 years Ambulatory Amenable to exon 44 skipping	BEL, ITA, ESP, GBR	NCT07037862 (ELEVATE-44)
Entrada	ELEVATE-45-201	Phase I & II	Duchenne Muscular Dystrophy 4 years to 20 years Ambulatory Amenable to exon 45 skipping	BEL, ITA, NLD, ESP, GBR	NCT07038824 (ELEVATE-45)
BioMarin Pharmaceutical	BMN 351	Phase I & II	Duchenne Muscular Dystrophy 4 years to 10 years Ambulatory Amenable to exon 51 skipping	CAN, ITA, NLD, ESP, TUR, GBR	NCT06280209
Gene Therapy					
REGENXBIO	RGX-202	Phase II & III	Duchenne Muscular Dystrophy 1 Year and older Ambulatory Mutation in Exons 18 and above	USA (AR, CA, CO, FL, GA, IL, IA, MA, OH, OR, TX, VA) CAN	NCT05693142 (AFFINITY DUCHENNE)
Precision BioSciences	PBGENE-DMD	Phase I & IIa	Duchenne Muscular Dystrophy 2 Years to 7 Years Ambulatory Mutation between Exons 45-55	TBD	NCT07429240 (FUNCTION-DMD)
Solid Biosciences	SGT-003	Phase I & II	Duchenne Muscular Dystrophy 0 Year to 17 Years Ambulatory and/or non-ambulatory Mutations Not within Exons 1-11, 42-45, 57-69	USA (AR, CA, GA, IL, MO, OH, OR, PA, VA, WA) CAN, ITA, GBR	NCT06138639 (INSPIRE DUCHENNE)

Insmed	INS1201	Phase I	Duchenne Muscular Dystrophy 2 Years to 4 Years Ambulatory Mutation between Exons 18 and 58	USA (AR, CA, GA, NY, OH, TN, VA)	NCT06817382 (ASCEND)
Sarepta	SRP-9001	Phase I	Duchenne Muscular Dystrophy 2 Years and older Cohort 8: Non-ambulatory	USA (CA, MO, OH, VA)	NCT04626674 (ENDEAVOR)
Sarepta	Gene Therapy long-term follow-up	Phase IV	Duchenne Muscular Dystrophy 4 Years and older Patients have been prescribed delandistrogene moxeparvovec Mutations Not within Exons 8-9	USA (AR, CA, CO, CT, DC, FL, IL, IN, KS, MI, NC, OH, OR, PA, TN, TX, VA, WA, WI)	NCT06270719 (ENDURE)
Anti-inflammatory					
Nationwide Children's Hospital Children's Hospital of Chicago Children's Hospital Medical Center, Cincinnati	Prednisolone	Phase IV	Duchenne Muscular Dystrophy 1 Month to 30 Months	USA (IL, OH, TX)	NCT05412394
Others					
Satellos Bioscience	SAT-3247	Phase II	Duchenne Muscular Dystrophy 7 Years to 9 years Ambulatory	USA (CA, CO, IL, KS, MD, MA, MO, OH, TX, VA, WA) AUS, CAN, SRB, GBR	NCT07287189 (BASECAMP)
Italfarmaco	Givinostat	Phase III	Duchenne Muscular Dystrophy 9 Years to 17 years Non-ambulatory	BEL, CAN, FRA, DEU, ITA, NLD, GBR	NCT05933057 (ULYSSES)
Sqy Therapeutics	SQY51	Phase I & IIa	Duchenne Muscular Dystrophy 6 Years and older ≥ 16 kg body weight Amenable to exon-51 skipping	FRA	NCT05753462 (AVANCE1)
Roche	Satralizumab	Phase II	Duchenne Muscular Dystrophy 8 Years to 17 Years Additional criteria for fracture-naïve and low-trauma fractures participants	USA (AR, CA, GA, MA, MI, MT, NY, TX, VA) DNK, ITA, POL, ESP, UKR	NCT06450639 (SHIELD DMD)
Sardocor Corp/Medera	SRD-001 (AAV1/SERCA2a)	Phase Ib	Duchenne Muscular Dystrophy 18 Years and older	USA (KS, OH)	NCT06224660 (MUSIC-DMD)